7 terminated. 7 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Terminated 7 |
| Phase 3 | 2 | Terminated 2 |
| Phase 1 | 1 | Terminated 1 |
Follow CSL Behring: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection Clazakizumab, Placebo - COVID-19 | Phase 2 | Terminated | Columbia University | 1 | 2020-05-18 | 2022-04-08 |
| The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant AAT, Placebo - Acute-graft-versus-host Disease | Phase 2 / Phase 3 | Terminated | CSL Behring | 222 | 2019-03-27 | 2026-09-09 |
| Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors CSL689, Eptacog alfa (activated) - Hemophilia A With Inhibitors, Hemophilia B With Inhibitors | Phase 2 / Phase 3 | Terminated | CSL Behring | 25 | 2015-07-23 | 2019-08-28 |
| Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease Placebo matching with BMS-945429, BMS-945429 - Crohn's Disease | Phase 2 | Terminated | CSL Behring | 72 | 2012-06-01 | 2021-12-03 |
| Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD) ALD518 - Acute GvHD | Phase 1 / Phase 2 | Terminated | CSL Behring | 3 | 2012-03-01 | 2021-02-17 |
| Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects ALD518, 0.9% saline - Oral Mucositis | Phase 2 | Terminated | CSL Behring | 76 | 2011-07-01 | 2021-05-11 |
| RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery Human fibrinogen concentrate, apheresis platelets - Heart Valve Disease, Coronary Artery Disease | Phase 2 | Terminated | Emory University | 26 | 2011-01-01 | 2018-06-21 |
COVID-19 (1) · Coronary Artery Disease (1) · Coronavirus Infections (1) · Crohn Disease (1) · Head and Neck Neoplasms (1) · Heart Valve Diseases (1) · Stomatitis (1)
clazakizumab (4) · Factor VII (1) · Fibrinogen (1) · Respreeza (1) · Saline Solution (1) · alpha 1-Antitrypsin (1)
United States (6) · Italy (4) · Germany (3) · Australia (2) · Austria (2) · Canada (2) · South Korea (2) · Spain (2) · United Kingdom (2) · Czechia (1) · France (1) · Georgia (1) · Hong Kong (1) · Hungary (1) · India (1)
David J. Cohen, MD (1) · Gautam Sreeram, MD (1) · Javier San Martin, MD FRCP (1) · Jeffrey Smith, MD FRCP (1) · Kenichi Tanaka, MD, MSc (1)
2018 (1)